[Chemosensitivity test for head and neck cancers].
The chemosensitivities of 27 fresh specimens of head and neck cancers were tested with MTT assay to study the practicability and accuracy of the assay for the examination of chemosensitivity in head and neck cancer patients. The chemosensitivities among cancers of different primary sites, pathologic types, histological differentiations, DNA ploidies and estrogen receptors were compared in an attempt to evaluate the choice of anticancer drugs for individual chemotherapy. Eight anticancer drugs: Methotroxate (MTX), Mitomycin C (MMC), fluorouracil (5-Fu), Carboplatin (CBDCA), Pingyangmycin (PYM), Homoharringtonine (HHA), Etoposid (VP16) and Vincristine (VCR) were included. The success rate of MTT assay in the present study was 92.6% and the accuracy was relatively high. The sensitivity sequence was PYM > HHA > MTX > CBDCA > MMC > 5-Fu > VCR > VP16, which suggested HHA should be recommended first to the chemotherapy of head and neck cancer. No chemosensitivity differences were found among different primary sites histological differentiations and estrogen receptors. The chemosensitivity of squamous cell carcinoma was significantly higher than that of adenoid cystic carcinoma. The chemosensitivity of aneuploid tumor was significantly higher than that of diploid.